The Medicine Accelerator (TMA) is a privately owned, science driven, diverse modality CDMO partner that specializes in bioprocess engineering, process development and GMP manufacturing to create scale-up strategies for effective and fully portable tech transfer and manufacturing control for CGT, vaccines, peptides, ATMPs, small and large molecules. TMA’s proprietary, first in class, iAchieve® cloud-based knowledge management platform tracks and curates data in real-time and provides visibility to every CMC decision made during a molecule’s journey. APC is a team of 300 strong with a 14-year track record of large pharma and biotech partnerships demonstrating significant process, recovery, timeline, and COGs improvements for mammalian, human, and microbial systems. Construction is ongoing to double our footprint and staff in 2026.
Taiwan Pavilion
Taiwan is located in the center of the Asia-Pacific region, with abundant medical resources, and diverse clusters of information and communication, semiconductor, and biomedical industries. It is suitable for the investment in development of precision health industries such as high-end medical materials, AI computing, and big data analysis. Taiwan medical device manufacturers have developed actively medical research and technology and we hope to cooperate with local industries, so it will be easier to enter the supply chain of major international brands. Metal Industries Research & Development Centre (MIRDC), a non-profit organization from Taiwan and assists Taiwan government to cultivate and reinforce the medical device industry in Taiwan. We also develop medical device products and technologies in industries including dental and orthopedic implants, devices, medical imaging, minimally invasive surgery instrument, and healthcare. | The biomedical industry is one of the six core strategic industries in Taiwan. It is an important power for Taiwan to play the leading role in global economy. With rich experiences of research, development and manufacturing, Taiwan excels in high-tech fields, clinical trials and biologics production. Continuing R&D support from government has created highly skilled workforce to innovate and advance the industry. Besides, Taiwan’s strategic location and grown-up supply chain make it an ideal partner for worldwide collaboration. There are more than 60 exhibitors and institutions in the Taiwan Pavilion this year, covering new drug development, CRO, CDMO, agriculture biotechnology, medical devices, precision medicine and smart health fields. Come and Join us to shape the future of precision health for all ages through collaboration and innovation with Taiwan’s thriving biomedical industry! | The biomedical industry is an important power for Taiwan to play the leading role in global economy. With rich experiences of research, development and manufacturing, Taiwan excels in high-tech fields, clinical trials and biologics production. Continuing R&D support from government has created highly skilled workforce to innovate and advance the industry. Besides, Taiwan’s strategic location and grown-up supply chain make it an ideal partner for worldwide collaboration. There are more than 60 exhibitors and institutions in the Taiwan Pavilion this year, covering new drug development, CRO, CDMO, agriculture biotechnology, medical devices, precision medicine and smart health fields. Come and Join us to shape the future of precision health for all ages through collaboration and innovation with Taiwan’s thriving biomedical industry! | BPIPO is honored to lead Taiwan’s delegation, featuring around 40 prominent companies and organizations specializing in new drug development, CDMO, regenerative medicine, agricultural biotechnology, precision medicine, and smart health. We warmly invite you to visit the Taiwan Pavilion and explore opportunities for collaboration. At our pavilion, you’ll discover not only innovative business partnerships but also insights into Taiwan’s supportive biomedical policies and unique research ecosystem. Taiwan has dedicated decades of effort to fostering a thriving biomedical industry, supported jointly by government initiatives and private sector innovation. This collaborative environment has successfully driven cross-domain growth and positioned Taiwan as a global biotechnology hub.
SyntheticGestalt KK
“DRUG DISCOVERY REIMAGINED: 90% LESS COST, 75% LESS TIME” [PIONEERING MOLECULAR AI INNOVATION] SyntheticGestalt has developed the world’s largest molecule-specialized AI foundation model, revolutionizing drug discovery and molecular design across industries. Founded in 2018 in Tokyo, we’re addressing a critical challenge: early-stage pharmaceutical R&D consumes 40% of total drug development costs while traditional AI approaches struggle with limited datasets and technical barriers. Our proprietary SG4D10B foundation model, trained on 10 billion compounds across 100+ tasks, captures four-dimensional molecular information for unprecedented prediction accuracy. Unlike repurposed language models, our architecture was built specifically for molecular science, delivering superior performance even with minimal training data. [PROVEN RESULTS ACROSS INDUSTRIES] Our technology has delivered transformative ROI through real-world applications: * Pharmaceutical Partners: Virtual screening of 38 billion compounds identified a novel MKNK2 inhibitor in just 3 months instead of 12, with 90% cost reduction * Beverage Industry: Reduced discovery timelines for functional ingredients from 5 years to 6 months, identifying 10 active candidates from a 250M compound library * Environmental Solutions: Discovered novel PET-degrading enzymes outperforming existing plastic recycling solutions Chemical Manufacturing: Identified enzymatic pathways enabling sustainable production processes These successes demonstrate our consistent ability to accelerate molecular discovery by 75% while reducing costs by 90% compared to traditional approaches. [FLEXIBLE BUSINESS MODELS] SyntheticGestalt offers engagement options tailored to client needs: * Foundation Model Access: Enterprise subscription to SG4D10B via AWS and Google Cloud Marketplaces * Strategic Research Collaborations: Fixed-fee discovery programs or milestone-based development partnerships * Compound Discovery: Direct IP transfer of novel molecules identified through our AI platform Our multidisciplinary team of AI experts, medicinal chemists, and computational biologists works directly with partners to maximize value delivery. [UNIQUE TECHNOLOGY ADVANTAGES] What sets our approach apart: * World’s Largest Molecular AI: Trained on 10 billion compounds—orders of magnitude beyond competitors * True 4D Representation: Captures complete structural and electronic properties for superior prediction accuracy * Minimal Data Requirements: Achieves high performance with significantly smaller datasets than traditional AI * Cross-Domain Applications: From small molecule drugs to industrial enzymes, materials, and beyond [APPLICATIONS BEYOND PHARMACEUTICALS] While pharmaceutical applications deliver dramatic ROI, our technology drives innovation across multiple industries: * Chemical Manufacturing: Enzyme discovery for greener production processes * Materials Science: Novel materials with precisely engineered properties * Agrichemicals: Safer, more effective crop protection solutions * Food & Beverage: Functional ingredients with targeted properties * Fragrance: Prediction of sensory characteristics in aroma compounds [GLOBAL EXPANSION] With successful partnerships in Japan with major corporations including Enamine and Asahi Group, we’re now expanding internationally, raising Series B funding to accelerate U.S. market entry. Our vision extends to designing multi-component molecular systems, optimizing synthetic pathways, predicting complex biological interactions, and creating autonomous discovery platforms—dramatically accelerating scientific innovation. [PARTNER WITH US AT BIO INTERNATIONAL 2025] Visit us at Booth #2265 in the Japan Pavilion or schedule a meeting through the BIO Partnering System to discuss: * How our technology can transform your specific R&D challenges * Collaborative research opportunities * Foundation model access options Join the organizations already leveraging our technology to achieve breakthrough results in molecular discovery with 90% less cost and 75% less time. [CONTACT INFORMATION] Location: Japan Pavilion, Booth #2265 Website: https://syntheticgestalt.com/en Email: d.morohashi@syntheticgestalt.com Partnering Contact: Daisuke Morohashi, Head of AI Business
Syngene International
Syngene International Ltd. is a leading Integrated Innovation Partner and CRDMO, for the global pharmaceutical, biopharma, biotechnology, and life sciences investment sectors. By combining discovery science, development expertise, and scalable manufacturing under one roof, we eliminate handoff delays, anticipate technical challenges, and align strategies to shorten timelines and reduce risk. As an innovation partner, we connect every stage from concept to IND. With expertise across biologics, ADCs, and targeted protein degradation, we deliver speed, scientific depth, and strategic alignment. Our proprietary SynTACs™ platform advances induced proximity-based therapeutics such as PROTACs, while our AI-driven ecosystem—Syn.AI™, SARchitect™, and SynTIPS™—optimizes design, accelerates analysis, and delivers actionable insights. Powered by our SynVent™ integrated discovery engine, we transform early-stage ideas into viable clinical candidates. Through versatile partnering structures and tailored business models, Syngene supports more than 400 global customers—including leading biotech innovators and multinational companies such as BMS, GSK, Zoetis, and Merck KGaA—to accelerate drug pipelines with capital efficiency, scientific rigor, and world-class manufacturing excellence. | . | Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s more than 5000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA. | Specialization – Syngene offers end-to-end services for mammalian and microbial systems, covering diverse modalities and therapeutic areas. This primarily includes mAbs, recombinant proteins, bispecific, biosimilars, and ADCs. About us – Syngene, a leading global CRDMO with over 30 years of experience solving complex R&D challenges, delivers integrated drug discovery, development, and manufacturing services across small and large molecules. Its diverse clientele ranges from global multinationals to small and medium-sized start-ups. Syngene helps biopharma companies accelerate large molecule therapies to market through integrated biologics CDMO services, with manufacturing facilities across the U.S. and India. With a GMP capacity of 50 KL in single-use bioreactors, featuring 500-, 2,000-, and 4,000-liter units designed to deliver economies of scale, Syngene offers innovative, flexible, and efficient solutions to its clientele.
SWISS Pavilion
Switzerland at BIO 2025: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2025 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2025. Join us in shaping the future of global health – the Swiss way. | Switzerland at BIO 2026: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2026 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2026. Join us in shaping the future of global health – the Swiss way. | Swissenviro was founded in 2015 by Urs Heutschi. It is a small, privately-owned company and the organizer of the SWISS Pavilion at international trade fairs for environmental technologies. With more than 20 years of experience, the international fair work is our area of expertise and forms the core of our work. The aim is to support export-orientated Swiss Cleantech SME to find buyers and business partners in international markets by encouraging international networking and direct B2B contacts on trade fairs and other events. By participation in a Joint Swiss Booth, the “SWISS Pavillon”, we are bringing together Swiss SMEs with professional trade visitors – potential future buyers, partners or suppliers. If desired, we gladly accompany and support the SME further on its business project resulting from this first customer contact. We closely work together with relevant Swiss environmental associations such as Cleantech Alps, VSA and Energie-Cluster. For our SWISS Pavilions we are supported by the MPK from “Switzerland Global Enterprise” (S-GE) and the “Swiss Federal Office for the Environment” (FOEN).
SUPERA PARQUE
SUPERA Park is an innovative environment that promotes knowledge transfer in several types of activities. It is responsible for attracting and retaining technology-based companies, with noteworthy mention to the Health, Biotechnology, Information Technology and Bioenergy industries. SUPERA Park was built within the University of São Paulo (USP) – one of the best universities in Brazil, Fact that makes it easier to find qualified people and hard science knowledge. SUPERA Park has many activities to support startups to validate and build a solid business model. Based on this, we have one of the best business incubator in Brazil (top 20 world universities in the 2019 UBI benchmark), 9 different laboratories for technical tests and validation, an international department and 3 clusters (health, software and beer) supported by our team. We also represent a number of startups that are looking for new partnerships and customers for their solutions. | SUPERA is the technology park of Ribeirão Preto, one of the most important scientific centers in the country. Our main programs are the Business Incubator, Open Innovation Program and Softlanding Program for international companies wishing to settle in Brazil. | SUPERA Innovation and Technology Park is a dynamic innovation ecosystem located in Ribeirão Preto, São Paulo, Brazil, and is linked to the University of São Paulo (USP) – Ribeirão Preto campus. SUPERA Park is a reference center for science, technology, and innovation, fostering entrepreneurship, knowledge-based businesses, and technological development. Core Mission: SUPERA Park supports the development and growth of startups, scale-ups, and innovative companies, particularly in the fields of biotechnology, life sciences, health, information technology, and advanced manufacturing. It provides infrastructure, business development support, and access to networks that drive innovation and competitiveness. Key Activities and Services: – Business Incubation and Acceleration: Programs for startups and scale-ups, offering mentoring, business modeling, market validation, and growth strategies. – Softlanding Programs: Support for international companies entering the Brazilian market and Brazilian companies aiming to internationalize. – Collaborative R&D Support: Facilitation of partnerships between companies, universities, and research centers for research, development, and innovation (R&D&I) projects. – Innovation Programs: Open innovation initiatives connecting corporations with startups and researchers to solve business challenges. – Infrastructure: High-standard office spaces, laboratories, coworking areas, and access to specialized facilities in biotechnology, pharmaceuticals, agritech, healthtech, and ICT. – Matchmaking and Networking: Connection to investors, corporate partners, academic experts, and government agencies to foster business and technology development. – International Cooperation: Support for international collaborative projects, technology transfer, and partnerships with global innovation ecosystems. Key Sectors of Focus: – Biotechnology – Pharmaceuticals and HealthTech – Medical Devices – Agritech and Bioinputs – Digital Health and ICT – Clean Technologies
Stämm
Stämm is an international biotechnology company that is revolutionizing the way biomanufacturing is done. Founded in 2016, it’s now based in the United States and has offices and labs in Argentina and Switzerland. The company offers advanced solutions for automated, continuous, and improved biologics & cell therapies production with a wide range of solutions that stem from their core solution, the Bioprocessor, to cell line development and an AI transomics platform. Stämm’s mission is to make bioprocesses easy, scalable, sustainable and repeatable inspired by nature’s solutions, unleashing the full potential of biotechnology and thus freeing their partners to focus on the disruptive discoveries that make an impact in people’s lives. The company is committed to providing the best possible solutions to accelerate life-changing therapies through flexible, future-ready facilities that meet the evolving needs of its clients and improve global health. Products & Services Stämm’s products and services are structured in three segments: 1. Biomanufacturing: Stämm’s core solution is a continuous, bubble-free Bioprocessor, a biomanufacturing platform with a novel 3D printed bioreactor that enhances yields, reduces costs, and minimizes footprint and energy consumption. Stämm’s approach enables a scalable,energy-efficient solution that provides an ideal cell growth environment. 2. Bio AI: Stämm is developing a transomics platform that leverages in-silico methods through their Multi-omic Network Atlas (MoNA™) allowing to map the biomolecular behaviour of cells with its experimental ambient conditions. With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet-lab assay design, execution and interpretation. Therefore achieving high precision biomolecular decision-making. 3.Bioenegineering: Stämm is developing state-of-the-art devices for Cell Line Development with automated cell engineering, clone outgrowth & screening for production of biologics. This is being done through a Bioengineering Platform, an engineering and sorting platform powered by a high-throughput automated system to streamline your workflow and a Clone Selection Platform, a specialized solution that automates clone selection and screening, monitoring the process to optimize your pipeline. Stämm’s is committed to providing a bio-innovative perspective capable of tackling the entire biomanufacturing pipeline
Staburo GmbH
Staburo GmbH is a data science company, specialized in biostatistics, programming (with R and SAS), data management and bioinformatics for healthcare projects. Our core competencies include Clinical Statistics, Translational Medicine & Biomarkers, Phase I, Data Transparency & Disclosure Services and Bioinformatics. Our customers are CROs (with small or no biometry department inhouse), biotech companies, international pharmaceutical companies (7 of the top 20) and medical device manufacturers.
SciSure
SciSure is the result of a bold, deliberate merger between two established names in digital lab technology: eLabNext, long respected for its ELN and LIMS capabilities, and SciShield, a trusted leader in EHS, compliance and lab safety. By combining our offerings, we have become the first Scientific Management Platform (SMP): a true home base for the modern lab. SciSure unites the needs of Scientists, EHS, and LabOps professionals in one connected solution, delivering a seamless experience for safe, efficient, and reproducible scientific advancement. Together, we’re shaping the future of lab digitalization—one platform, every workflow. | x
Sciomics
Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance. At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform. | Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients’ quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. | Sciomics has a robust immuno-proteomics platform for the development of protein biomarker panels as well as for the support of pre-clinical programs. On this basis we have established our own internal protein biomarker development pipeline and are offering CRO services for our customers in pharma and biotech. Currently, we are building a new venture bridging the gap between biomarker discovery, verification, and the introduction of our biomarker panels into the IVD market. The most advanced project focuses on scioAKI – a four-protein biomarker panel for an early and precise diagnosis of Acute Kidney Injury (AKI, for more details see asset scioAKI). Please get in touch if you are interested in partnering with us or investing in this endeavor. Our internal biomarker development pipeline, with the scioAKI project being our main program, is based on the scioDiscover platform. scioDiscover enables a robust combination of our proteomics data with AI-approaches for the definition of high-performance biomarker panels, both regarding sensitivity and specificity. As the platform is completely immuno-based, findings can be easily transferred to ELISA or similar tools for clinical routine use. In addition to our internal biomarker development pipeline, we offer CRO services based on our scioDiscover protein profiling platform and are welcoming R&D collaborations as well. Main applications are – the discovery and validation of novel biomarkers, – drug target screening, – the characterization of disease models, – the analysis of pathway activity as well as – mode-of-action studies. One of the key advantages in collaborating with us is our team of scientific experts that takes pride in custom-tailoring every project and consulting as well as supporting clients throughout the project. Our full-service ranges from discussing experimental designs to in-depth data analysis and yields a comprehensive study report. Fast and cost-efficient, Sciomics’ powerful high-content, high-throughput antibody array platform delivers reliable results that can be easily translated into validation or clinical assays. Thereby, we are a strong partner in generating value and opening new avenues for biomarker discovery, as well as target discovery and verification as well as preclinical drug development programs.